Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Completion Rate
    0%(0/1)
    Active Trials
    0(0%)
    Terminated
    1(33%)

    Phase Distribution

    Phase 2
    1
    33%
    Phase 1/2
    2
    67%

    Phase Distribution

    0

    Early Stage

    3

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1/2Combined phases
    2(66.7%)
    Phase 2Efficacy & side effects
    1(33.3%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 3 finished

    Non-Completion Rate

    100.0%

    3 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Terminated(3)

    Detailed Status

    Withdrawn2
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    0.0%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 1/22 (66.7%)
    Phase 21 (33.3%)

    Trials by Status

    terminated133%
    withdrawn267%

    Recent Activity

    0 active trials
    Showing 3 of 3
    withdrawnphase_1_2

    Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    NCT01101581
    terminatedphase_1_2

    Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

    NCT01147393
    withdrawnphase_2

    Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL

    NCT02844530

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT01101581Phase 1/2

    Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    Withdrawn
    NCT01147393Phase 1/2

    Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

    Terminated
    NCT02844530Phase 2

    Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL

    Withdrawn

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3